Table 7 Results of one-way sensitivity analyses for base-case scenario
| Â | Values | Estimated ICER |
|---|---|---|
Base Case | Â | $19420 |
Death hazard ratio of Met+SU to Met+DPP-4i | 1.67 (−10%) | $23760 |
Death hazard ratio of Met+SU to Met+DPP-4i | 2.04 (+ 10%) | $16760 |
Metformin treatment failure | 0.035 (−25%) | $19440 |
Metformin treatment failure | 0.058 (+ 25%) | $19560 |
Met+DPP-4i treatment failure | 0.010 (−25%) | $18970 |
Met+DPP-4i treatment failure | 0.017 (+ 25%) | $20010 |
Met+SU treatment failure | 0.040 (−25%) | $19410 |
Met+SU treatment failure | 0.067 (+ 25%) | $19590 |
Severe hypoglycemia in Met+SU | 0.012 (−25%) | $19500 |
Severe hypoglycemia in Met+SU | 0.020 (+ 25%) | $19500 |
Severe hypoglycemia in insulin glargine triple therapy | 0.008 (−25%) | $19500 |
Severe hypoglycemia in insulin glargine triple therapy | 0.013 (+ 25%) | $19500 |
Weight gain in the first year of Met+SU | 0.383 (−25%) | $19520 |
Weight gain in the first year of Met+SU | 0.638(+ 25%) | $19470 |
Myocardial infarction in Met+DPP-4i | 0.003(−25%) | $19380 |
Myocardial infarction in Met+DPP-4i | 0.005(+ 25%) | $19620 |
Heart failure in Met+DPP-4i | 0.013(−25%) | $19120 |
Heart failure in Met+DPP-4i | 0.021(+ 25%) | $19880 |
Stroke in Met+DPP-4i | 0.002(−25%) | $19470 |
Stroke in Met+DPP-4i | 0.003(+ 25%) | $19520 |
Heart failure in Met+SU | 0.015(−25%) | $19790 |
Heart failure in Met+SU | 0.025(+ 25%) | $19210 |
Stroke in Met+SU | 0.015(−25%) | $19660 |
Stroke in Met+SU | 0.025(+ 25%) | $19340 |
Costs of myocardial infarction | $13970(−25%) | $19430 |
Costs of myocardial infarction | $23284(+ 25%) | $19570 |
Costs of heart failure | $10589(−25%) | $19450 |
Costs of heart failure | $17648(+ 25%) | $19550 |
Costs of stroke | $5954(−25%) | $19660 |
Costs of stroke | $9924(+ 25%) | $19340 |
Costs of severe hypoglycemia | $110(−25%) | $19500 |
Costs of severe hypoglycemia | $183(+ 25%) | $19500 |
Costs of weight gain | $217(−25%) | $19520 |
Costs of weight gain | $361(+ 25%) | $19470 |
Costs of insulin glargine | $2917(−20%) | $20320 |
Costs of insulin glargine | $4375(+ 20%) | $18680 |
Death rate | 0.019 (age 60–70) / 0.046 (age 71–80) / 0.096 (age 81–85) (−10%) | $20780 |
Death rate | 0.024 (age 60–70) / 0.057 (age 71–80) / 0.118 (age 81–85) (+ 10%) | $18470 |
Time horizon | 20 years (− 20%) | $24250 |
Time horizon | 30 years (+ 20%) | $17580 |
Same cardiovascular event rates from 2Â years after dual therapy | MI; 0.004 / HF; 0.02 / Stroke; 0.02 | $20420 |
Age at start of metformin monotherapy | 55 (−8%) | $21360 |
Age at start of metformin monotherapy | 65 (+ 8%) | $18120 |